HLA -A B DR for HSCT

What is HLA A, B, DR LOCI TYPING PCR Test?

This test identifies an individual’s HLA type across key class I (HLA‑A, ‑B, ‑C) and class II (HLA‑DR, ‑DQ) loci using a bead/array-based platform (often referred to as “HistoSPOT”/Luminex-style or DNA-based typing), providing low-to-high resolution allele assignments. It defines the specific HLA alleles a person carries, which are critical markers of histocompatibility that guide donor–recipient matching and inform disease associations.

Why consider HLA -A B DR for HSCT in Aluva?

• Transplant matching: Improves compatibility for kidney, marrow/hematopoietic stem cell, and other organ/tissue transplants, reducing acute and chronic rejection and graft loss.

• Immunologic risk assessment: Informs donor selection, allocation strategies, and the intensity of immunosuppression; foundational for virtual crossmatch and donor-specific antibody interpretation.

• Disease association and pharmacogenetic relevance: Certain HLA types associate with autoimmune diseases (e.g., HLA-B27 with spondyloarthropathy) and drug hypersensitivity (e.g., abacavir-HLA-B*57:01), and HLA profiling aids risk evaluation where indicated.

Who should get this HLA -A B DR for HSCT in Aluva?

• Transplant candidates and potential living donors for kidney, liver, heart, lung, pancreas, or HSCT who require precise HLA matching at A, B, and DR to optimize outcomes.

• Patients being evaluated for or monitored after transplant where accurate HLA typing is needed to interpret donor-specific antibody results and guide rejection risk management.

• Individuals undergoing workup for select autoimmune conditions or drug hypersensitivity where specific HLA associations are clinically actionable as per clinician request.

Class I HLA antigens include HLA-A, B, and C molecules; class II, which includes HLA-DR, -DQ, and -DP loci, are on antigen-presenting cells; and class III contains genes for proteins that have immune functionality.

HLA class I typing is used to identify HLA-matched platelets for alloimmunized refractory patients and identify presence of HLA antigens associated with a number of diseases or as drug hypersensitivity markers class I HLA antigens include A, B, and C loci.